ABSTRACT
Objective:To investigate the clinical efficacy of 125I seed implantation combined with anlotinib hydrochloride in the treatment of non-small cell lung cancer (NSCLC). Methods:61 cases of NSCLC patients were enrolled, of which 30 cases (observation group) received 125I seed implantation combined with anlotinib treatment, and 31 cases (control group) received 125I seed implantation only. To evaluate the curative effect and adverse reactions of all patients, the carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuroendocrine enolase (NSE), squamous cell carcinoma antigen (SCC) in the peripheral blood of the two groups was measured before the treatment and at 1 and 3 months after the treatment. Results:The effective rates in the observation group were 90.00% and 93.33%, the effective rates in the control group were 67.74% and 74.19% at 1 and 3 months after the treatment, respectively, and the difference in efficacy between the two groups was statistically significant ( χ2=4.504, P=0.034 vs. χ2=4.075, P=0.044). There was no significant difference in the incidence of adverse reactions between the two groups of patients after treatment ( P=0.785). At 1 and 3 months after the treatment, the levels of CEA, CYFRA21-1, NSE and SCC in the peripheral blood of the two groups of patients were lower than those before the treatment (all P<0.05). Conclusions:125I seed implantation combined with anlotinib hydrochloride is safe for the treatment of advanced non-small cell lung cancer, and has promotion value.
ABSTRACT
Objective To discuss the clinical value of CT-guided percutaneous embedding of 125I seeds in combined chemotherapy with TP regime for non-small cell lung cancer(NSCLC). Methods Thirty two patients with NSCLC received CT-guided percutancous embedding of 125I particles, TP chemotherapy plan (paclitaxcl 135 mg/m2 /d1, cisplatin 75 mg/m2/d2 ～ 4 ) for four cycles after operation. The follow-up CT for observing therapeutic effects at 1, 3, 6, 12 month after 125I seeds implantation was undertaken. Results All cases were controlled effectively after one month revealed by CT follow up. The efficiency of tumor curing at 3, 6, 12 month were 87.5%, 90.63%, 92.31% respectively. None of the patients showed radiation injury and particle migration, and all of them had only slight side effects. Conclusion CT-guided percutaneous embedding of 125I seeds in combination with chemotherapy for non-small cell lung cancer is an effective and safe method, possessing valuable utilization clinically.